Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

Alnylam Elects Amy Schulman to its Board of Directors

Published: Saturday, July 05, 2014
Last Updated: Saturday, July 05, 2014
Bookmark and Share
Appointment of industry leader brings broad strategic, commercial, and legal experience to board.

Alnylam Pharmaceuticals, Inc. has announced the election of Amy W. Schulman to its Board of Directors. Ms. Schulman is the former Executive Vice President and General Counsel of Pfizer Inc., and served as the Business Unit Lead for Pfizer's Consumer Healthcare business. She currently serves on the faculty of Harvard Business School as a Senior Lecturer.

"Amy is a recognized leader in the development and growth of global pharmaceutical businesses, and she will bring this expertise to our Board as we continue to build Alnylam as a leading biotechnology company. As the former General Counsel at Pfizer, Amy also brings deep legal expertise to our Board," said John Maraganore, Ph.D., Chief Executive Officer of Alnylam. "Given our robust clinical progress and our potential transition to a commercial company in the coming years, Amy's addition to our Board comes at an opportune time as we advance RNAi therapeutics to patients."

"I am excited to join the Board of Alnylam, a first-in-class innovation-based biotechnology company, and a pioneer in advancing an entirely new class of high impact medicines with RNAi therapeutics," said Ms. Schulman. "The tremendous progress Alnylam has made in its clinical efforts has yielded very encouraging results. I look forward to working with the outstanding team of management and directors in place today and contributing to the company's value creation strategy and execution."

Ms. Schulman originally joined Pfizer in 2008 as General Counsel and saw the company through its $68 billion acquisition of Wyeth. In 2010, in addition to her role as General Counsel, Ms. Schulman became President and General Manager of Pfizer's $2.1 billion global infant formula and nutrition business. Once that business was sold to Nestlé she assumed responsibility for the Consumer Healthcare business.

Before joining Pfizer, she was a partner at DLA Piper, where she was a member of the Board and Executive Policy Committees, and built and led the international law firm's mass tort and class-action practice. Ms. Schulman's accomplishments have earned her recognition from leading publications and organizations.

In 2013 Fortune magazine named her one of the "50 Most Powerful Women in Business." That same year, The American Lawyer named her one of the "Top 50 Innovators," and The National Law Journal named her one of "The 100 Most Influential Lawyers in America."

The American Bar Association honored her with the Margaret Brent Women Lawyers of Achievement award in 2012. A Phi Beta Kappa graduate of Wesleyan University, Ms. Schulman earned her J.D. from Yale Law School in 1989. She serves on the Board of Directors of The Brookings Institution and Wesleyan University.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Alnylam Announces USPTO Issues Patent Covering RNAi Therapeutics
New '277 McSwiggen patent includes broad, sequence-independent claims for chemically modified siRNAs targeting the HBV genome.
Saturday, June 14, 2014
Alnylam Presents New Pre-Clinical Data with Development Candidate for ALN-CC5
Company on track to file IND application in late 2014 and now guides to report initial clinical results in mid-2015.
Thursday, June 12, 2014
Alnylam Initiates Phase II Clinical Trial with ALN-TTRsc
Company expects to present data in late 2014, and start pivotal phase III trial with ALN-TTRsc in TTR cardiac amyloidosis in late 2014.
Monday, December 30, 2013
Alnylam Presents New Pre-clinical Data on ALN-AT3
New results demonstrate an expanded therapeutic index for AT knockdown and complete correction of aPTT in models of hemophilia.
Tuesday, December 10, 2013
Alnylam Files CTA to Initiate a Phase I Study for ALN-AT3
Company expects to initiate phase I study in early 2014 with interim data from hemophilia subjects by year-end 2014.
Friday, November 01, 2013
Alnylam Scientists Present Pre-clinical Data with ALN-CC5, an RNAi Therapeutic
New research demonstrates potent, dose-dependent, and durable silencing of serum C5 for the treatment of complement-mediated diseases.
Friday, June 21, 2013
Alnylam Reports Positive ALN-TTR02 Clinical Data
Results of clinical study demonstrate rapid, dose-dependent, durable, and specific knockdown of TTR, the disease-causing protein in TTR-mediated Amyloidosis (ATTR).
Tuesday, July 24, 2012
Alnylam and Collaborators Publish New Pre-clinical Results
New paper published in blood shows potent and selective induction of liver erythropoietin through silencing of EglN genes.
Wednesday, June 13, 2012
Scientific News
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos